Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEO trial of short versus standard pegylated interferon alfa-2a plus ribavirin for hepatitis C genotype 2 or 3
ISRCTN29259563Phase 4Completed
- Sponsor
- Club Hepatology Hospital
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (3 arms), sponsored by Club Hepatology Hospital. Primary endpoint: Sustained virological response. Started May 2006; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ISRCTN29259563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29259563.